Land: USA
Sprog: engelsk
Kilde: NLM (National Library of Medicine)
eletriptan hydrobromide (UNII: M41W832TA3) (eletriptan - UNII:22QOO9B8KI)
Quality Care Products, LLC
ORAL
PRESCRIPTION DRUG
Eletriptan hydrobromide tablets are indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use: - Use only if a clear diagnosis of migraine has been established. If a patient has no response to the first migraine attack treated with eletriptan hydrobromide tablets, reconsider the diagnosis of migraine before eletriptan hydrobromide tablets are administered to treat any subsequent attacks. - Eletriptan hydrobromide tablets are not intended for the prevention of migraine attacks. - Safety and effectiveness of eletriptan hydrobromide tablets have not been established for cluster headache. Eletriptan hydrobromide tablets are contraindicated in patients with: - Ischemic coronary artery disease (CAD) (angina pectoris, history of myocardial infarction, or documented silent ischemia) or coronary artery vasospasm, including Prinzmetal’s angina [see Warnings and Precautions (5.1 )] . - Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction
Eletriptan hydrobromide tabletscontaining 20 mg or 40 mg eletriptan (base) as the hydrobromide salt. Eletriptan hydrobromide tabletsare orange, round, biconvex, film-coated tablets with appropriate debossing. They are supplied in the following strengths and package configurations: Eletriptan hydrobromide tablets Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].
Abbreviated New Drug Application
ELETRIPTAN HYDROBROMIDE- ELETRIPTAN HYDROBROMIDE TABLET, FILM COATED QUALITY CARE PRODUCTS, LLC ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE ELETRIPTAN HYDROBROMIDE TABLETS SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR ELETRIPTAN HYDROBROMIDE TABLETS. ELETRIPTAN HYDROBROMIDE TABLETS, FOR ORAL USE INITIAL U.S. APPROVAL: 2002 INDICATIONS AND USAGE Eletriptan hydrobromide tablets is a serotonin (5-HT ) receptor agonist (triptan) indicated for the acute treatment of migraine with or without aura in adults (1) Limitations of Use: Use only after a clear diagnosis of migraine has been established (1) Not indicated for the prophylactic therapy of migraine (1) Not indicated for the treatment of cluster headache (1) DOSAGE AND ADMINISTRATION Single dose: 20 mg or 40 mg (2) Maximum single dose: 40 mg (2) May repeat dose after 2 hours if needed; not to exceed 80 mg in any 24-hour period (2) DOSAGE FORMS AND STRENGTHS Tablets: 20 mg and 40 mg (3) CONTRAINDICATIONS History of coronary artery disease (CAD) or coronary artery vasospasm (4) Wolff-Parkinson-White syndrome or other cardiac accessory conduction pathway disorders (4) History of stroke, transient ischemic attack, or history or current evidence of hemiplegic or basilar migraine (4) Peripheral vascular disease (4) Ischemic bowel disease (4) Uncontrolled hypertension (4) Within 24 hours of treatment with another 5-HT agonist, or an ergotamine containing medication (4) Hypersensitivity to eletriptan hydrobromide tablets (angioedema and anaphylaxis seen) (4) Within at least 72 hours of treatment with the following potent CYP3A4 inhibitors: ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, or nelfinavir (4) WARNINGS AND PRECAUTIONS Myocardial ischemia/infarction or Prinzmetal’s angina: Perform cardiac evaluation in patients with multiple cardiovascular risk factors (5.1) Arrhythmias: Discontinue eletriptan hydrobromide tablets if occurs (5.2) Chest/throat/ Læs hele dokumentet